Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, 200031, China; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, 200031, China.
South China Advanced Institute for Soft Matter Science and Technology, School of Molecular Science and Engineering, South China University of Technology, Guangzhou, 510640, China; Guangdong Provincial Key Laboratory of Functional and Intelligent Hybrid Materials and Devices, South China University of Technology, Guangzhou, 510640, China.
Biomaterials. 2021 Jan;268:120600. doi: 10.1016/j.biomaterials.2020.120600. Epub 2020 Dec 17.
Oxidative stress is a hallmark of the pathophysiogenesis of retinal ischemia. The direct delivery of antioxidant enzymes such as superoxide dismutase (SOD) into retinal cells provides a promising option for the down-regulation of oxidative stress in retinal ischemia, however, efficient intracellular protein delivery remains a major challenge for this application. Here, a boronic acid-rich polymer was used for the intracellular delivery of SOD both in vitro and in vivo. The polymer assembled with SOD into uniform nanoparticles with high binding affinity, and transported the cargo protein into several cell lines with maintained bioactivity and low cytotoxicity. We investigated the intraocular biodistribution, therapeutic efficacy and safety of the SOD nanoformulation in a retinal ischemia/reperfusion (I/R) injury model. After intravitreal injection, the nanoparticles rapidly diffused through the vitreous and penetrated into retinal ganglion cells (RGCs). Compared to free SOD, the nanoformulation exhibited much enhanced therapeutic efficacy with reduced RGC apoptosis and protected retinal function. Enzymatic results confirmed that the SOD nanoformulation reduced malondialdehyde expression and increased glutathione level in the ocular tissues, and thereby down-regulated oxidative stress and prevented RGC loss. Overall, this work offers a new therapeutic option for the treatment of retinal ischemic disorders by direct delivery of antioxidant proteins.
氧化应激是视网膜缺血病理生理学的标志。将抗氧化酶(如超氧化物歧化酶[SOD])直接递送至视网膜细胞为下调视网膜缺血中的氧化应激提供了一个很有前途的选择,然而,有效的细胞内蛋白质递送仍然是该应用的主要挑战。在这里,富硼酸的聚合物被用于 SOD 的细胞内递送来进行体外和体内实验。该聚合物与 SOD 组装成具有高结合亲和力的均匀纳米颗粒,并将货物蛋白运送到几种具有维持生物活性和低细胞毒性的细胞系中。我们在视网膜缺血/再灌注(I/R)损伤模型中研究了 SOD 纳米制剂的眼内分布、治疗效果和安全性。玻璃体内注射后,纳米颗粒迅速通过玻璃体扩散并穿透至视网膜神经节细胞(RGC)中。与游离 SOD 相比,纳米制剂表现出增强的治疗效果,RGC 凋亡减少,视网膜功能得到保护。酶学结果证实,SOD 纳米制剂降低了眼部组织中的丙二醛表达并增加了谷胱甘肽水平,从而下调了氧化应激并防止了 RGC 损失。总的来说,这项工作通过直接递送抗氧化蛋白为治疗视网膜缺血性疾病提供了一种新的治疗选择。